We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BURL:NYSEBurlington Stores, Inc. Analysis

Data as of 2026-05-23 - not real-time

$324.51

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Burlington Stores (BURL) is trading at $324.51, comfortably above its 20‑day SMA ($306.64) and 50‑day SMA ($318.36), and well above the 200‑day SMA ($291.87), indicating a short‑term bullish bias. The RSI sits at 58.6, suggesting momentum is still positive but not overbought, while the MACD histogram is positive (+2.53) with a bullish crossover, reinforcing the upside bias. Volume is increasing and the stock holds a strong support near $280.6 with resistance at $331.3, leaving limited room for a near‑term pull‑back.
Fundamentally, BURL posted 11.3% revenue growth, a solid gross margin of 44% and an impressive ROE of 38%, yet it carries a massive debt‑to‑equity ratio of 332% and a PE of 34.1 (forward PE 24.0), signaling that the market has priced in strong growth expectations. Analyst consensus remains a “Buy” with a median 12‑month target of $370, but recent headlines note a 2.6% dip on higher oil prices and a new Hold rating from Truist, highlighting discretionary‑spending sensitivity. The combination of high valuation, elevated leverage, and a volatile 30‑day price swing (36.7%) suggests caution, even as the Fear & Greed Index reads “Extreme Greed.”

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above key moving averages
  • Bullish MACD crossover
  • Increasing volume and supportive technical levels

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong revenue growth and high ROE
  • Elevated debt‑to‑equity ratio
  • Valuation multiples remain high relative to peers

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Off‑price retail model shows resilience
  • Debt burden may constrain future cash generation
  • Analyst price targets imply modest upside but risk of overvaluation

Key Metrics & Analysis

Financial Health

Revenue Growth11.30%
Profit Margin5.28%
P/E Ratio34.1
ROE38.40%
ROA5.78%
Debt/Equity332.46
P/B Ratio11.1
Op. Cash Flow$1.2B
Free Cash Flow$105.3M

Technical Analysis

TrendNeutral
RSI58.6
Support$280.57
Resistance$331.25
MA 20$306.64
MA 50$318.36
MA 200$291.87
MACDBullish
VolumeIncreasing
Fear & Greed Index91.61

Valuation

Target Price$367.40
Upside/Downside13.22%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.12
Volatility36.72%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.